Find FDA Investigational New Drug (IND) Submissions for Cardiology/Vascular Diseases in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sodium Nitrite

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: JanOne

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 06, 2020

            Details:

            CATO SMS will assist JanOne in expanding its current FDA authorized Investigational New Drug (IND) for JAN101, an oral, sustained release formulation of sodium nitrite, to treat vascular complications to potentially restore endothelial cell function in COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MAT9001

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: BTIG

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: IPO January 09, 2020

            Details:

            Matinas BioPharma anticipates using the net proceeds from the offering primarily for ongoing development for its product candidates, namely MAT9001, and its lipid nano-crystal (“LNC”) platform delivery technology